We report a case of haemophagocytic syndrome (HPS) occurring after allogeneic bone marrow transplantation (BMT) for acute promyelocytic leukaemia (APL) in a patient in fourth complete remission (CR). Anticytomegalovirus (CMV) antibody (Ab) was negative in this patient before BMT. BMT was performed from an HLA-identical unrelated donor who was positive for CMV Ab. After bone marrow engraftment and haematological recovery, severe acute graft-versus-host disease (GVHD) developed. This patient was treated with methylprednisolone in addition to cyclosporin A (CsA). Acute GVHD showed partial improvement, but CMV antigenaemia was observed. Despite administration of gancyclovir and immunoglobulin, CMV antigenaemia showed no improvement and HPS developed. As no other infections or malignancies were observed, we suspect that CMV infection was the trigger for development of HPS. Keywords: haemophagocytic syndrome; bone marrow transplantation; acute promyelocytic leukaemia; cytomegalovirus The haemophagocytic syndromes (HPS) are rare and frequently lethal disorders characterised by several clinical features including fever, organomegaly, cytopenia, hypertriglyceridaemia or hypofibrinogenaemia and ingestion of haematopoietic cells by activated macrophages.
The haemophagocytic syndromes (HPS) are rare and frequently lethal disorders characterised by several clinical features including fever, organomegaly, cytopenia, hypertriglyceridaemia or hypofibrinogenaemia and ingestion of haematopoietic cells by activated macrophages. 1 Haemophagocytic lymphohistiocytosis (HLH), representative of HPS, is characterised by non-malignant diffuse infiltration of lymphocytes and macrophages. 2 Although the detailed pathogenic mechanism of developing HPS is not understood, a large number of recent clinical studies [3] [4] [5] [6] have shown that the underlying features of this disorder are attributable to hypercytokinaemia due to release of several acute inflammatory cytokines, especially interferon-gamma Correspondence: M Sato, Third Department of Internal Medicine, Gunma University School of Medicine, Showa-machi 3-39-22, Maebashi, Gunma 371-8511, Japan Received 31 March 1998; accepted 19 July 1998 (IFN-gamma). These observations suggest that hypercytokinaemia and the cytokine network triggered by IFNgamma may play crucial roles in this syndrome.
Due to its high success rate in the treatment of acquired malignant haematological disorders and congenital immune disorders including HLH, 7 bone marrow transplantation (BMT) is used extensively worldwide. Viral infection is a frequent serious complication in addition to graft-versushost disease (GVHD) following BMT. After engraftment, viral infection may occur as the result of incomplete immunoreconstitution and/or be associated with GVHD and immunosuppressive treatment. 8 However, HPS is a rare complication after BMT. We report a case of HPS after BMT, and suggest that HPS might be associated with cytomegalovirus (CMV) infection.
Case report
A 40-year-old woman diagnosed as having acute promyelocytic leukaemia (APL) in fourth complete remission (CR) was admitted to our hospital on 6 August 1996, to undergo BMT. She had received conventional chemotherapy with or without all-trans retinoic acid (ATRA) from January 1992. On admission, she had no abnormal findings on physical examination. Laboratory findings including haematological, biochemical, and serological parameters were also normal. She was negative for both anti-CMV IgG and IgM antibody (Ab). Bone marrow showed CR status with a normal karyotype. Cytogenetic CR was confirmed by reverse transcription polymerase chain reaction (RT-PCR) for PML/RAR␣ fusion transcripts. She received total body irradiation (TBI) of 3 Gy daily for 4 consecutive days (total 12 Gy) and VP-16 20 mg/kg for 3 consecutive days (total 60 mg/kg) as conditioning for BMT. On 27 September BMT was performed from an HLA-identical unrelated donor who had a high titre of CMV Ab. The patient and her unrelated donor were genetically different at the HLA class I, B locus: 4002 (patient) vs 4006 (donor). GVHD prophylaxis was cyclosporin A (CsA) 3 mg/kg by continuous daily i.v. infusion and short-term methotrexate at 15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6 and 11. High titre of immunogloblin against CMV (250 mg/kg) was administered. Successful engraftment was documented at day 23 after BMT. Recurrent watery diarrhoea became severe on day 25. Fibrescopic examination revealed mucosal acute GVHD (grade III) of the whole colon. Therefore, methylprednisolone (2 mg/kg) therapy was started on day 31. On day 54 after BMT, she complained of mild dyspnea, and the results of blood gas analysis were: PaO 2 86.9 mmHg and AaDO 2 21.56. Computed tomography showed diffuse granular regions in both lungs. At this time, CMV antigen levels were highly elevated ( Figure 1 ) in circulating neutrophils (cells positive for CMV early antigen C10, C11 accounted for 130 and 148 of 150 000 neutrophils, respectively). Bone marrow maintained normal cellularity without either relapse or haemophagocytosis. Administration of gancyclovir (10 mg/kg) and O 2 therapy were started. As the GVHD did not respond sufficiently to immunosuppressive therapy, she underwent methylprednisolone pulse therapy (methylprednisolone 20 mg/kg for the initial 3 days, tapered thereafter). Five days after this treatment, she had fever, abdominal pain and dyspnea. Her haemoglobin level (Hb) was 8.5 g/dl, platelet count (PLT) 30 × 10 9 /l and leucocyte count (WBC) 20.0 × 10 9 /l with neutrophilia. Coagulation tests indicated the occurrence of disseminated intravascular coagulation (DIC). Biochemical analysis showed lactate dehydrogenase (LDH) 7038 IU/l, triglycerides 484 mg/dl and ferritin 7267.5 ng/ml. Hepatosplenomegaly developed. Although the CMV antigen positive neutrophil level was further elevated, human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) were negative as determined by RT-PCR. Adenovirus, herpes simplex virus (HSV) and varisella-zoster virus (VZV) were serologically negative. Bone marrow was normocellular with an increased macrophage number containing ingested erythrocytes, neutrophils and erythroblasts (Figure 2 ). From these observations, she was diagnosed as having HPS. Despite administration of VP-16 (1 mg/kg once daily i.v. for 5 consecutive days) combined with immunogloblin 250 mg/kg for 3 days, she died on day 64 after BMT due to multi-organ failure. Cytokine measurement of sampled sera showed significant elevation of interleukin-1 beta (IL-1 beta) at the time of CMV infection and HPS development. However, no significant elevation of IFN-gamma or tumor necrosis factor-alpha (TNF-alpha) was observed.
Discussion
We describe a fulminant case of HPS following BMT from an unrelated donor for therapy-resistant APL. This case of HPS might have been associated with prior CMV infection. Since Risdall et al 1 which is termed HLH and is represented by infection-associated haemophagocytic syndrome (IAHS). Furthermore, IAHS has been reported to be associated with infection by a variety of organisms including bacteria, 9 tuberculosis 10 and some viruses (eg EBV, 11 CMV, 12 HSV, 1 HHV-6 13 and adenoviruses 1 ). The development of HPS in this case was associated with CMV infection: (1) systemic CMV antigenaemia appeared prior to HPS development, but this infection did not respond to gancyclovir and consequently HPS developed; (2) during the clinical course of BMT, no haematological relapse or secondary malignancies including lymphoma were observed; and (3) there was no evidence of other related bacterial, fungal or other viral infections.
Several recent reports have indicated that hypercytokinaemia plays a major role in the development of HPS. Therefore, we examined related cytokines including IFN-gamma, TNFalpha and IL-1 beta in this patient. As summarised in Figure 1 , we found a marked elevation of serum IL-1 beta, which remains at normal levels in patients with active acute GVHD. However, except for a period during conditioning therapy, IFN-gamma and TNF-alpha levels stayed within the normal range. Imashuku et al 14 reported a patient with HSVassociated HPS, in whom elevation of serum IFN-gamma level appeared to precede other inflammatory cytokines. IFNgamma is presumed to act as a trigger for the cytokine network in VAHS. As a result of the sensitivity of the enzymelinked immunosorbent assay (ELISA) for IFN-gamma, we were unable to adequately assess serum IFN-gamma levels in this patient. However, IFN-gamma level was slightly elevated within the normal range on day 50. Based on this observation, it is possible that serum IFN-gamma was elevated before the appearance of CMV antigenaemia.
After BMT, patients are at risk of HPS because of viral infections due to immunodeficiency, administration of steroids, immunosuppressants and/or cytokines for the treatment of GVHD, and reduction in the period of myelosuppression. However, HPS is an extremely rare complication after BMT. Reardon et al 15 reported the first case of VAHS following allogeneic BMT in second CR of acute lymphocytic leukaemia (ALL). This and the present case shared certain similarities in different clinical settings. These patients suffered from severe refractory acute GVHD of the entire colon and intra-intestinal hemorrhage which might have been induced by acute GVHD and/or coagulopathy. Recent studies using the non-lethal murine hemorrhage model demonstrated that haemorrhage stress induces release of acute inflammatory cytokines 16 including TNF, IL-1 and interleukin 6 (IL-6), and depression of APC function. 17 Therefore, it is possible that the large amounts of tissue damage induced by progression of GVHD in either the gastrointestinal tract or systemic skin ultimately causes severe immunodisturbance. Another similarity between the cases, is that large amounts of immunosuppressants were used to treat acute GVHD. Therefore, these factors might allow the development of HPS following BMT, either directly or indirectly. Although viral infection has been suggested as a trigger for HPS development, HPS following BMT was caused by concurrent events including accumulated cytokines and severe immunodisturbance, and did not have a simple, isolated aetiology in the early phase of immunoreconstitution. We emphasise that this case of HPS was associated with allogeneic BMT. To define the origin of haemophagocytic processes, or how progression to haemophagocytic syndrome occurs, further studies of cytokine mobilisation and immune mechanisms are necessary in patients after BMT.
